Background: D-Limonene, a monoterpene from citrus fruit has been found to have
| INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome.
Reciprocal translocation t(9;22)(q34;q11) generates the Bcr-Abl chimeric gene which leads to constitutive activation of the tyrosine kinase domain. 1 First line treatment with tyrosine kinase inhibitors (TKIs) has an excellent response in CML patients, with improved life expectancy. However, resistance to a currently used TKI, imatinib, has developed in the chronic (35%), accelerated (45%) and blastic (90%) phases of the disease. This is associated with a poor prognosis in CML patients, and has increased the need for new drug for the treatment of the disease. Natural products are now rapidly emerging
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and appear promising for the development of new anti-cancer drugs. 2, 3 D-Limonene, a monocyclic monoterpene present in citrus fruits, has been found to have chemopreventive and chemotherapeutic activity against various types of cancers. [4] [5] [6] [7] [8] [9] Oral administration of D-Limonene inhibited the growth of rodent pancreatic, mammary, and gastric carcinogenesis and exhibited anticancer activity. 7, 8, [10] [11] [12] [13] In our previous studies, we reported that D-Limonene inhibited the growth of K562 cells in vitro without producing any toxicity in primary hepatocytes isolated from the mouse. 14 In this study, we evaluated the in vivo effect of D-Limonene in immunocompromised C57BL/6 mice.
The chick embryo model offers a number of unique advantages for studying the complex, multistep process of tumor cell metastasis.
It serves as a naturally immunodeficient host capable of sustaining grafted tissues and cells, without restrictions, because of its underdeveloped lymphoid system. 15, 16 The chorioallantoic membrane (CAM) provides a uniquely supportive environment for primary tumor formation, and is a source of angiogenesis, the formation of new blood vessels from an existing vasculature. 17 Angiogenesis has a crucial role in growth, metastasis and dissemination of tumors.
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The imbalance between pro-and antiangiogenic factors causes pathogenesis and progression of hematologic neoplasias. 19 Increases in a number of angiogenic factors can significantly increase the number of vessels in the bone marrow of patients with CML. 20, 21 The present study aimed to evaluate the effect of D-Limonene on angiogenesis using an in vivo chick CAM assay. 
| MATERIALS AND METHODS

| Materials
| Cell and culture conditions
The human CML cell line (K562) was obtained from NCCS (National Centre for Cell Science, Pune, India). 22, 23 
| Experimental animals and housing conditions
| Chick CAM assay
Fertilized chick eggs were procured from Jesal Agro Ltd, Gandhinagar, Gujarat, India at the time of experiments. Chick eggs were incubated at 37°C and 60% humidity in an egg incubator (A. P.
Poultry Equipments, Hyderabad, Telangana, India) in sterile conditions. On the third day of incubation, eggs were sterilized with isopropyl alcohol and an air sac was made by gently aspirating 2 ml albumin, which is enough to bring the membrane down. | 329
| Statistical analysis
Statistical analysis was performed by using GraphPad Prism software (version 5.03, Graph Pad Software Inc., La Jolla, CA, USA). Data are presented as means ± SEM. Significant differences were determined by one-way ANOVA followed by Bonferroni multiple comparisons.
P < 0.05 was considered to be statistically significant.
| RESULTS AND DISCUSSION
Chronic myeloid leukemia is a condition in which an acquired mutation of genes controls the proliferation and development of cells present in the blood and bone marrow. 27 The Philadelphia chromosome resulting from this mutation has the ability to cause proliferation of myeloblasts. 28 Imatinib and other TKIs are losing their effectiveness in the treatment of CML due to developed resistance. Adjuvant therapy or a combination of drugs may be a better alternative in the treatment of disease. The C57BL/6 mice were injected with K562 cells via tail vein injection followed by immunosuppression and the peripheral blood was examined weekly for circulating blasts using Giemsa staining. The blast cells were differentiated from normal blood cells under the microscope by the larger diameter of the cells (≈28 μm), the presence of prominent nuclei, reduced cytoplasm and a higher nuclear/cytoplasmic ratio, which confirms the establishment of model. 29 By the fourth week after the transplantation of K562 cells in C57BL/6 mice, Giemsa differential staining of peripheral blood smears showed large numbers of blast cells in the disease control or K562 treated group compared with untreated group. 29 As the disease progressed, changes in haematological parameters were noted. By the fourth week after K562 cell injection, significant increases in WBC, NEU, and LYM counts were observed, compared to 0 weeks, whereas significant reductions in RBC count and Hb content were seen, confirming the establishment of the model (Figure 1) . No significant changes in platelet count and other parameters were noted.
| Effect of D-Limonene on the growth of K562 cells in C57BL/6 mice
In CML, the disease progression leads to an increase in the number of granulocytes, which is the reason for the increased numbers of total WBCs, NEUs, and LYMs. However, the significant reduction in Haematological parameters show significant reductions in WBC, NEU, and LYM counts 1 wk after tail vein injection of K562 cells compared to week 0. No significant changes were observed in RBC count and Hb content. Four weeks after tail vein injection, significant increases in WBC, NEU, and LYM counts and reductions in RBC count and Hb content were noted compared to week 0. Data shown are the means ± SEM (n = 10), *P < 0.05, **P < 0.01 and ***P < 0.001 vs week 0 reduction in WBC and NEU counts compared to the DC group. The change in LYM count was not significant with 0.5 mg/kg D-Limonene, but at doses of 1.0 and 1.5 mg/kg a significant dose-dependent reduction was observed compared to the DC group. Changes in RBC count and Hb content were non-significant with D-Limonene treatment (Figure 2 ). D-Limonene at a dose of 1.5 mg/kg produced the greatest effect on disease progression by reducing WBC, NEU, and LYM counts and increasing RBC count and Hb content compared to other treatment group, which suggests it has potential for use in the treatment for CML. | 331 in the progression of CML by affecting the vascularity of bone marrow or leukemic cells. CAM assays have been widely used to study the effect of various compounds on angiogenesis because of their simplicity, cost-effectiveness and reproducibility. 19 We evaluated the effect of D-Limonene on angiogenesis using the CAM assay.
On 
